Kiran Musunuru, MD, PhD, MPH, ML

Call 800-789-7366
Penn Medicine Provider

About me

  • Barry J. Gertz Professor for Translational Research
  • Professor of Pediatrics

My education and training

  • Medical School: NewYork-Presbyterian / Weill Cornell Medical Center
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill
  • Fellowship: Johns Hopkins Hospital
  • Fellowship: Massachusetts General Hospital

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Musunuru is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Jiang AY, Cristian A, Brooks DL, Feierman ER, Chen PZ, Whittaker MN, Pierce SE, Sakai HA, Chen H, Liu D, Randolph PB, Li AH, Hsu A, Omo-Lamai SO, Tao YA, Owusu-Amo B, Wang X, Wang X, Musunuru K, Liu DR. Efficient prime editing in vivo and in vitro using lipid nanoparticles , Nat Nanotechnol: 2026

Gautier MK, King K, Han Y, Said H, Alameh MG, Wang X, Hong X, Musunuru K, Ahrens-Nicklas RC. In vivo adenine base editing rescues brain biochemistry and improves motor deficits in a common phenylketonuria variant , Mol Ther Adv, 34: 2026,201760

Feierman ER, Whittaker MN, Quigley A, Brooks DL, McVeigh P, Nan AX, Hsu A, Said H, Soliman OY, Giovenco R, Davidson BL, Alameh MG, Liu DR, Wang X, Musunuru K, Ahrens-Nicklas RC. Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform , Am J Hum Genet, 113: 2026,891-899

Ambardekar AV, Bhatt A, Hoekstra M, Kelly MA, Musunuru K, Natarajan P. Gene editing therapy in cardiovascular disease: 2026 ACC scientific statement: a report of the American College of Cardiology , J Am Coll Cardiol: 2026

Kahn E, Cannon P, Musunuru K. ASGCT's 2025 breakthroughs in targeted in vivo gene editing: meeting summary and insights , Mol Ther, 34: 2026,1298-1300

McDermott-Roe C, Lv W, Shao Y, Hoshino A, Arany Z, Musunuru K. CRISPR/Cas9 screens implicate RARA and SPNS1 in doxorubicin cardiotoxicity , JACC CardioOncol: 2026,48-61

Schwab RD, Degaramo D, Hong SJ, Bi X, Faruqi A, Aguilar W, Brookens SK, Keane JT, Liu F, Musunuru K, Rader DJ, Posey AD Jr. Chimeric antigen receptor regulatory T cells targeted against oxidized low-density lipoprotein reduce atherosclerotic plaque development , Circulation, 153: 2026,319-337

Musunuru K. The dawn of interventional genetics , Am J Hum Genet, 113: 2026,1-2

Angelini Stewart A, Ahrens-Nicklas RC, Tsai SQ, Musunuru K, Giannikopoulos P, Clelland CD. Measurement and clinical interpretation of CRISPR off-targets , Nat Genet: 2026,20-27

Yu TW, Vitarello J, Musunuru K, Ahrens-Nicklas RC, Liu DR, Mellion ML, Urnov F, Yan W, Chunduru S, Barrett D, Flotte TR, Woodcock J. Response to the FDA's proposed pathway for individualized genetic therapies , Mol Ther, 34: 2026,1-2